Motasim Sirhan, formerly of the Guidant Corporation, founded Aventec, a medical device company, in 1999. We invested in Avantec shortly after it was founded and were its sole institutional investor.
Key Insights and Vision
- In select medical device markets, such as interventional cardiology, companies earn pharmaceutical company-like margins despite dramatically shorter and less costly regulatory approval processes.
- Even in international markets where medical device approval timelines are shorter than the US, companies still earn high margins.
- Interventional cardiologists, unlike other medical professions, will more easily switch stent systems for improvements in performance specifications.
- With Mr.Sirhan's leadership a low profile, tight knit, highly innovative, team could accomplish with a limited budget what most companies struggle to accomplish with hundred million dollar R&D budgets.
- Develop and quickly bring to international markets a best in class current generation stent system to quickly begin generating revenues, while
- Investing in the development of next generation systems
Company’s Strategic and Operational Achievements
- Developed and launched best in class bare metal stents in the Japanese market within two years of start-up.
- Made considerable progress in developing next generation product including first in-man studies.
- Eighteen months after incorporation, and accumulated burn of less than $5 million, Avantec was cash flow positive.
- In 2003, Avantec was sold to its Japanese manufacturer and distributor, Goodman Ltd., for $165 million (10X return on our initial investment)
- Recently, Mr. Sirhan and Invus have formed a new joint venture to fund and develop new products at the intersection of medical devices and drug therapy.